Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer

Clinical Cancer Research

Volumn 12, Issue 4, 2006, Pages 1192-1200

  De Silva Rudland, Suzete ^a   Martin, Lee ^b,d   Roshanlall, Chandeene ^b,e   Winstanley, John ^b,c,f   Leinster, Samuel ^b,c,g   Platt Higgins, Angela ^a   Carroll, Joe ^a   West, Christopher ^c   Barraclough, Roger ^a   Rudland, Philip ^a,c  

^a Center for Cell Imaging   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^e MACCLESFIELD DISTRICT GENERAL HOSPITAL   (United Kingdom)

^f ROYAL BOLTON HOSPITAL   (United Kingdom)

^g UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALVASCULIN; ESTROGEN RECEPTOR ALPHA; OSTEOPONTIN;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER SURVIVAL; ENDOTHELIUM CELL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR VASCULARIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOPONTIN; PROGNOSIS; REGRESSION ANALYSIS; S100 PROTEINS; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 33644748253     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1580     Document Type: Article

References (55)

1. Early Breast Trialist Collaborative Group. Worldwide evidence. In: Treatment of early breast cancer. Oxford (United Kingdom): Oxford University Press; 1990.
2. Kamby C. The pattern of metastasis in human breast cancer: methodological aspects and influence of prognostic factors. Cancer Treat Rev 1990;17:37-61.
3. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:357-77.
4. Carter C, Allen C, Henson D. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
5. Robertson JFR, Bates K, Pearson D, Blarney RW, Nicolson RI. Comparison of two estrogen receptor assays in the prediction of clinical course of patients with advanced breast cancer. Br J Cancer 1992;65:727-30.
6. Esteban JM, Ahn C, Battifora H, Fielder B. Predictive value of estrogen receptors evaluated by quantitative immunocytochemical analysis in breast cancer. Am J Clin Pathol 1994;102:S9-12.
7. Winstanley JHR, Croton R, Holt SM, et al. Oestrogen receptors: their long term significance in breast cancer. Br J Cancer 1991;63:99-101.
8. Bosari S, Lee AKC, Deleltis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast cancer. Hum Pathol 1992;23:755-61.
9. Gasparini G, Weidner N, Bevilacqua P, et al. Tumour microvessel density, p53 expression, tumour size and peritumoural lymphatic invasion are relevant prognostic markers in node negative breast carcinoma. J Clin Oncol 1994;12:454-66.
10. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkey count, and computer image analysis. J Pathol 1995;177:275-83.
11. Lemster SJ. Impact of molecular biology on the clinical management of breast cancer In: Rudland PS, Fernig D, Leinster S, Lunt G, editors. Mammary development and cancer. London: Portland Press, 1998. p. 185-92.
12. Folkman J. What is the evidence that tumors are angiogenesis dependent. J Natl Cancer Inst 1990;82:4-6.
13. Dunnington DJ, Hughes CM, Monaghan P, Rudland PS. Phenotypic instability of rat mammary tumor epithelial cells. J Natl Cancer Inst 1983;71:1227-40.
14. Dunnington DJ, Kim U, Hughes CM, Monaghan P, Rudland PS. Lack of production of myoepithelial variants by cloned epithelial cell lines derived from the TMT-081 metastasizing rat mammary tumor. Cancer Res 1984;44:5338-46.
15. Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991;63:447-50.
16. Davies B, Davies M, Gibbs F, Barraclough R, Rudland PS. Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ ras-1. Oncogene 1993;8:999-1008.
17. Dates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastatic-related gene product in a rodent mammary tumor model. Oncogene 1996;13:97-104.
18. Nikitenko LL, Lloyd BH, Rudland PS, Fear S, Barraclough R. Localisation by in situ hybridisation of S100A4 (p9Ka) mRNA in primary human breast tumour specimens. Int J Cancer 2000;86:219-28.
19. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994;145:610-23.
20. Hirota S, Ito A, Nagoshi J, et al. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab Invest 1995;72:64-9.
21. Bellahcène A, Castronova V. Increased expression of osteonectin and osteopontin, two bone matrix proteins in human breast cancer. Am J Pathol 1995;46:95-100.
22. Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997;3:605-11.
23. Rudland PS, Platt-Higgins A, Renshaw C, et al. Prognostic significance of the metastasis inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 2000;60:1595-1603.
24. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002;62:3417-27.
25. 2+-binding proteins of the S100 family in malignant human breast cancer cell lines and biopsy samples. Int J Cancer 1994;57:684-90.
26. Mazzucchelli L. Protein S100A4: too long over-looked by pathologists. Am J Pathol 2002;160:7-13.
27. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer Predict Oncol 1998;79:502-8.
28. Pedersen KB, Nesland JM, Fodstad O, Maelandsmo G. Expression of S100A4, E-cadherin, alpha-and beta-catenin in breast cancer biopsies. Br J Cancer 2002;18:1281-6.
29. Kim YW, Park Y-K, Lee J, Ko SW, Yang MH. Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci 1998;13:652-7.
30. Martin L, Green B, Renshaw C, et al. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer 1997;76:1046-54.
31. Gorski JP, Griffin D, Dudley G, et al. Bone acidic glycoprotein-75 is a major synthetic product of osteoblastic cells and localized as 75- and/or 50-kDa forms in mineralized phases of bone and growth plate in serum. J Biol Chem 1990;265:14956-63.
32. Gibbs FEM, Wilkinson MC, Rudland PS, Barraclough R. Interactions in vitro of p9Ka, the rat S100-related, metastasis-inducing, calcium-binding protein. J Biol Chem 1994;269:18992-9.
33. Gibbs F, Barraclough R, Platt-Higgins A, Rudland PS, Wilkinson M, Parry E. Immunocytochemical distribution of the calcium-binding protein p9Ka in normal rat tissues: variations in the cellular location in different tissues. J Histochem Cytochem 1995;43:169-80.
34. Fisher LW, Stubbs JT, Young MF. Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins. Acta Orthop Scand 1995;66:61-5.
35. Young MF, Kerr JM, Termine JD, et al. cDNA cloning, mRNA distribution and heterogeneity, chromosomal localization, and RFLP analysis of human osteopontin (OPN). Genomics 1990;7:491-502.
36. Platt-Higgins AM, Renshaw CA, West CR, et al. Comparison of the metastasis-inducing protein S100A4 (p9Ka) with other prognostic markers in human breast cancer. Int J Cancer Predict Oncol 2000;89:198-208.
37. Curran RC, Gregory J. The unmasking of antigens in paraffin sections of tissue by trypsin. Experientia 1977;33:1400-1.
38. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast cancer. N Engl J Med 1991;324:1-8.
39. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991. p. 403-5.
40. Cox DR. Regression models and life tables. J R Stat Soc B (Lond) 1972;34:187-202.
41. Ambartsumian N, Klingelhöfer J, Grigorian M, et al. The metastasis-associated Mts1 (S100A4) protein could act as an angiogenic factor. Oncogene 2001;20:4685-95.
42. El-Tanani M, Fernig DG, Barraclough R, Green C, Rudland PS. Differential modulation of transcriptional activity of estrogen receptors by direct protein interactions with the T cell factor family of transcription factors. J Biol Chem 2001;276:41675-82.
43. Schmidt-Hansen B, Ornas D, Grigorian M, et al. Extracellular S100A4 (mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 2004;23:5487-95.
44. Takenaga K, Nakamura Y, Sakiyama S. Expression of calcium binding protein pEL98 (mts1) during differentiation of human promyelocytic leukaemia HL-60 cells. Biochem Biophys Res Commun 1994;202:94-101.
45. Ford HL, Salim MM, Chakravarty R, Aluiddin V, Zain SB. Expression of Mts1, a metastasis-associated gene, increases motility but not invasion of a nonmetastatic mouse mammary adenocarcinoma cell line. Oncogene 1995;11:2067-75.
46. Jenkinson SR, Barraclough R, West CR, Rudland PS. S100A4 regulates cell motility and invasion in an in vitro model for breast cancer metastasis. Br J Cancer 2004;90:253-62.
47. Liaw L, Skinner MP, Raines EW, et al. The adhesive and migratory effects of osteopontin are mediated by distinct surface integrins. J Clin Invest 1995;95:713-24.
48. Moye VE, Barraclough R, West C, Rudland PS. Osteopontin expression correlates with adhesive and metastatic potential in metastasis-inducing DNA-transfected rat mammary cell lines. Br J Cancer 2004;90:1796-802.
49. Davies MPA, Rudland PS, Robertson L, Parry EW, Barraclough R. Expression of calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene 1996;13:1631-7.
50. Kang Y, Siegel PM, Shu W, et al. A multi-genic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
51. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406:532-5.
52. Agrawal P, Chen T, Irby R, et al. Osteopontin identified as a lead marker of colon cancer progression using pooled sample expression profiling. J Natl Cancer Inst 2002;94:513-21.
53. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
54. Khanna C, Khan J, Nguyen P, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001;61:3750-9.
55. van de Vijver HJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.